Ikapharmindo Putramas Tbk. Total Liabilities
Ikapharmindo Putramas Tbk. total liabilities. Based on the latest financial reports, Ikapharmindo Putramas Tbk. (IKPM) has total liabilities worth Rp239.93 Billion IDR (≈ $14.06 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Ikapharmindo Putramas Tbk. to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Ikapharmindo Putramas Tbk. (2022–2024)
Total liabilities of Ikapharmindo Putramas Tbk. from 2022 to 2024. This chart illustrates how Ikapharmindo Putramas Tbk.'s total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Ikapharmindo Putramas Tbk. to measure how efficiently the company converts operating cash flow to free cash.
Ikapharmindo Putramas Tbk. Competitors by Total Liabilities
The table below lists competitors of Ikapharmindo Putramas Tbk. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metro Bank PLC
LSE:MTRO
|
UK | GBX15.73 Billion |
|
Castle Peak Holdings Public Company Limited
BK:CPH
|
Thailand | ฿598.14 Million |
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
USA | $17.70 Million |
|
PC Direct Inc
KQ:051380
|
Korea | ₩78.31 Billion |
|
Czerwona Torebka
WAR:CZT
|
Poland | zł188.96 Million |
|
OXE Marine AB
ST:OXE
|
Sweden | Skr163.98 Million |
|
Greenland Mines Ltd
NASDAQ:GRML
|
USA | $7.11 Million |
|
Taruga Minerals Ltd
AU:TAR
|
Australia | AU$269.24K |
Liability Composition Analysis (2022–2024)
This chart breaks down Ikapharmindo Putramas Tbk.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Ikapharmindo Putramas Tbk..
Liquidity & Leverage Metrics
Ikapharmindo Putramas Tbk. Total Liabilities Ratios Explained
Ikapharmindo Putramas Tbk. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ikapharmindo Putramas Tbk.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ikapharmindo Putramas Tbk. (2022–2024)
The table below shows the annual total liabilities of Ikapharmindo Putramas Tbk. from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp245.25 Billion ≈ $14.37 Million |
+12.16% |
| 2023-12-31 | Rp218.67 Billion ≈ $12.81 Million |
+3.70% |
| 2022-12-31 | Rp210.85 Billion ≈ $12.36 Million |
-- |
About Ikapharmindo Putramas Tbk.
PT Ikapharmindo Putramas Tbk engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. It operates through three segments: Non Pharma, Pharma, and Contract Manufacturing. The company offers prescription medicines in the areas of neurology, psychiatry, dermatology, nephrology, gastroenterology, cardiology, pulmonology, antibiotics, generics, and… Read more